Immunosensing procedures for carcinoembryonic antigen using graphene and nanocomposites

Show simple item record

dc.contributor.author Luong, John H. T.
dc.contributor.author Vashist, Sandeep Kumar
dc.date.accessioned 2018-01-17T11:09:53Z
dc.date.available 2018-01-17T11:09:53Z
dc.date.issued 2015-11-18
dc.identifier.citation Luong, J. H. T. and Vashist, S. K. (2017) ‘Immunosensing procedures for carcinoembryonic antigen using graphene and nanocomposites’, Biosensors and Bioelectronics, 89(1), pp. 293-304. doi: 10.1016/j.bios.2015.11.053 en
dc.identifier.volume 89 en
dc.identifier.issued 1 en
dc.identifier.startpage 293 en
dc.identifier.endpage 304 en
dc.identifier.issn 0956-5663
dc.identifier.issn 1873-4235
dc.identifier.uri http://hdl.handle.net/10468/5285
dc.identifier.doi 10.1016/j.bios.2015.11.053
dc.description.abstract Two-dimensional (2D) graphene, sp2-hybridized carbon, and its two major derivatives, graphene oxide (GO) and reduced graphene oxide (rGO) have played an important role in immunoassays (IAs) and immunosensing (IMS) platforms for the detection of carcinoembryonic antigen (CEA), an implicated tumor biomarker found in several types of cancer. The graphene family with high surface area is functionalized to form stable nanocomposites with gold nanoparticles (AuNPs) and electron mediators. The capture anti-CEA antibody (Ab) with high density can be anchored on AuNPs of such composites to provide remarkable detection sensitivity, significantly below the level found in normal subjects and cancer patients. Electrochemical and fluorescence/chemiluminescence-quenching properties of graphene-based nanocomposites are exploited in various detection schemes. Future endeavors are envisioned for the development of an array platform with high-throughput for CEA together with other tumor biomarkers and C-reactive protein, a universal biomarker for infection and inflammation. The ongoing efforts dedicated to the replacement of a lab-based detector by a cellphone with smart applications will further enable cost-effective and frequent monitoring of CEA in order to establish its clinical relevance and provide tools for real-time monitoring of patients during chemotherapy. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier B.V. en
dc.rights © 2017, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. en
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Graphene en
dc.subject Graphene oxide en
dc.subject Reduced graphene oxide en
dc.subject Carcinoembryonic antigen en
dc.subject Immunoassay en
dc.subject Immunosensing platform en
dc.subject Electrochemical sensing en
dc.subject Chemiluminescence en
dc.subject Fluorescence quenching en
dc.title Immunosensing procedures for carcinoembryonic antigen using graphene and nanocomposites en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother John Luong, Chemistry, University College Cork, Cork, Ireland. T: +353-21-490-3000 E: j.luong@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Accepted Version en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Biosensors and Bioelectronics en


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2017, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. Except where otherwise noted, this item's license is described as © 2017, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement